Related Experiment Video
Updated: May 19, 2026
Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
Preclinical strategies targeted at non-small-cell lung cancer signalling pathways with striking translational fallout
Roberto E Favoni1, Angela Alama
1Department of Experimental Medicine, University of Genoa, Via Leon Battista Alberti, 2 c/o Laboratory of Gene Transfer, IRCCS AOU San Martino-IST, Largo Rosanna Benzi, 10-16132 Genoa, Italy. robertofavoni@tin.it
Abstract:
Over the past decades, a plethora of cytotoxic agents, administered alone or in combinations, have been prescribed for the treatment of non-small-cell lung cancer (NSCLC) but improvements regarding patient outcome remain disappointing. Therefore, additional therapeutic strategies are urgently required to increase response rate and survival. By the time researchers had begun to understand the processes involved in NSCLC development, the genetic aetiology of lung cancer had been progressively defined. The constitutive activation of receptor tyrosine kinases and their downstream signalling pathways has opened encouraging avenues of investigation for NSCLC treatment. Several new targeted compounds have evolved from preclinical to clinical settings to affect growth factor pathways of NSCLC, and their therapeutic implications will be reviewed and discussed here.
Insights
Despite decades of cytotoxic chemotherapy for non-small-cell lung cancer (NSCLC), patient outcomes remain poor. New targeted therapies focusing on receptor tyrosine kinases offer promising strategies to improve NSCLC treatment response and survival rates.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Cytotoxic chemotherapy has been the standard treatment for non-small-cell lung cancer (NSCLC) for decades.
- Despite extensive use, cytotoxic agents have yielded disappointing improvements in patient outcomes and survival rates.
- There is an urgent need for novel therapeutic strategies to enhance treatment efficacy in NSCLC.
Purpose of the Study:
- To review and discuss the therapeutic implications of new targeted compounds for NSCLC.
- To explore the role of receptor tyrosine kinases and downstream signaling pathways in NSCLC development and treatment.
- To highlight advancements in targeted therapies that affect growth factor pathways in NSCLC.
Main Methods:
- Literature review of preclinical and clinical studies on targeted therapies for NSCLC.
- Analysis of the genetic etiology and molecular pathways involved in NSCLC.
- Discussion of the evolution of targeted compounds from laboratory research to clinical application.
Main Results:
- The genetic underpinnings of lung cancer, including NSCLC, have been increasingly defined.
- Constitutive activation of receptor tyrosine kinases and associated signaling pathways presents promising therapeutic targets.
- Several targeted compounds have progressed to clinical trials, demonstrating potential to impact NSCLC growth factor pathways.
Conclusions:
- Targeted therapies directed at specific molecular pathways represent a significant advancement in NSCLC treatment.
- Understanding the genetic landscape of NSCLC is crucial for developing effective personalized treatment strategies.
- Further investigation and clinical application of targeted agents are essential to improve patient survival and response rates in NSCLC.
